Literature DB >> 26472615

Confocal Laser Endomicroscopy in the Management of Endoscopically Treated Upper Urinary Tract Transitional Cell Carcinoma: Preliminary Data.

Luca Villa1,2, Jonathan Cloutier1, Jean-Francois Cotè3, Andrea Salonia2,4, Francesco Montorsi2,4, Olivier Traxer1.   

Abstract

PURPOSE: To describe our initial experience with confocal laser endomicroscopy (CLE) for the evaluation and treatment of patients with upper urinary tract transitional cell carcinoma (UUT-TCC).
MATERIALS AND METHODS: Preliminary data were analyzed from 11 patients with suspicion of UUT-TCC scheduled for flexible ureteroscopy (f-URS) and consensual holmium-YAG laser tumor ablation. CLE was performed before endoscopic biopsy and laser photoablation of the suspected lesion using a 3F-diameter flexible probe UroFlex™ B (Cellvizio® system; Mauna Kea Technologies, Paris, France), which allows to obtain microscopic resolution imaging (3.5 μm), with a field of view of 325 μm and a depth of tissue imaging of 40 to 70 μm. Video sequences were analyzed offline and thereafter compared with histopathologic findings.
RESULTS: CLE technique was feasible and showed good quality imaging in all patients. Overall, the Cellvizio system provided reliable images of healthy urothelium when the probe was pointed toward normal tissue, showing umbrella cells on the surface and vessels in the lamina propria. Moreover, CLE displayed the characteristic features of high-density cellular aggregates and fibrovascular stalks in four patients with pathologically confirmed low-grade UUT-TCC. In the patient with pathologically confirmed high-grade UUT-TCC, more distorted microarchitecture and tortuous vessels were clearly recognized with CLE.
CONCLUSIONS: These preliminary data showed the feasibility of CLE technique when applied to the diagnosis of UUT-TCC. Further clinical studies are required to confirm CLE accuracy in distinguishing healthy urothelial tissue from malignant lesions, thus helping clinicians in targeting ureteroscopic biopsy and improving the conservative management of UUT-TCC patients.

Entities:  

Mesh:

Year:  2015        PMID: 26472615     DOI: 10.1089/end.2015.0644

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  6 in total

Review 1.  Are we closer to seeing carcinoma in situ in the upper urinary tract?

Authors:  Sławomir G Kata; Omar Aboumarzouk
Journal:  Cent European J Urol       Date:  2016-04-26

2.  Novel real-time optical imaging modalities for the detection of neoplastic lesions in urology: a systematic review.

Authors:  Oliver Brunckhorst; Qi Jia Ong; Daniel Elson; Erik Mayer
Journal:  Surg Endosc       Date:  2018-11-12       Impact factor: 4.584

Review 3.  Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma.

Authors:  Grzegorz Fojecki; Anders Magnusson; Olivier Traxer; Joyce Baard; Palle Jörn Sloth Osther; Georg Jaremko; Christian Seitz; Thomas Knoll; Guido Giusti; Marianne Brehmer
Journal:  World J Urol       Date:  2019-03-26       Impact factor: 4.226

4.  Confocal Laser Endomicroscopy for the Diagnosis of Urothelial Carcinoma in the Bladder and the Upper Urinary Tract: Protocols for Two Prospective Explorative Studies.

Authors:  Esmee Iml Liem; Jan Erik Freund; Joyce Baard; D Martijn de Bruin; M Pilar Laguna Pes; C Dilara Savci-Heijink; Ton G van Leeuwen; Theo M de Reijke; Jean Jmch de la Rosette
Journal:  JMIR Res Protoc       Date:  2018-02-07

5.  Treatment of upper tract urothelial carcinoma with ureteroscopy and thulium laser: a retrospective single center study.

Authors:  Jin Wen; Zhi G Ji; Han Z Li
Journal:  BMC Cancer       Date:  2018-02-17       Impact factor: 4.430

6.  Multi-Wavelength Fluorescence in Image-Guided Surgery, Clinical Feasibility and Future Perspectives.

Authors:  Florian van Beurden; Danny M van Willigen; Borivoj Vojnovic; Matthias N van Oosterom; Oscar R Brouwer; Henk G van der Poel; Hisataka Kobayashi; Fijs W B van Leeuwen; Tessa Buckle
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.